Table 3.

Target therapies (part I).

Electrolyte disorder	Drug	Incidence (%) Type of study	Mechanism(s)
Hyponatremia	Cixutumumab Bevacizumab Ado-trastuzumab Ipilimumab, Nivolumab Nivolumab Icrucumab, Etaracizumab Volociximab Brivanib, Imatinib, Dasatinib,Cediranib Nilotinib,Sorafenib, Sunitinib, Gefinitib, Pazopanib, Afatinib, Bosutinib Temsirolimus, Everolimus Interferon-alpha, Levamisole, Pentostatine Interferon-alpha Elacytarabine, Interleukin-2, Eribulin mesylate Bortezomib	25 (D) (71) n.a. (A) Brivanib and Cetuximab 63.4 (D); Pazopanib 31.7 (D); Gefitinib 1 (D) (6); Cediranib 65 (D); 35(<120 mmol/L) (72)	Blockade of IGF-1 receptor (71, 73) SIADH; Nephrotic Syndrome (69, 70) CSWS (74) Adrenal insufficiency due to autoimmune hypophysitis (75, 76) Interstitial nephritis, autoimmune adrenalitis (77, 78) SIADH (?) (79, 80) SIADH (34, 81–83) Aldosterone resistance (84, 85) SIADH (86–89) Hyperglicemia (90) Unclear (91–93) SIADH (?) (94, 95) TLS (96)

Incidence and type of study column: the letter after the percentage indicates the type of evidence available: A isolated case; B case series; C pharmacovigilance notifications or registry; D observational study, clinical trial, metanalysis of clinical trials. n.a. not available. References in bracket square. CSWS Cerebral Sal wasting Syndrome; IGF-1, Insulin-like growth factor-1; SIADH, Syndrome of inappropriate antidiuretic hormone secretion; TLS, Tumor Lysis Syndrome.